Hypogonadism
FDA recommends removing black box warning for CV risk from all testosterone product labels
The FDA has recommended several labeling changes to all approved testosterone replacement therapy products based on the agency’s review of several studies, according to a release.
Patients on testosterone replacement therapy may have increased risk for ACL injury
Patients using testosterone replacement therapy for at least 3 months may have an increased risk for ACL injuries, according to recently published data.
Hypogonadism may greatly increase mortality odds for hospitalized adults with asthma
NEW ORLEANS — Adults with asthma and hypogonadism have greatly increased risk for mortality during hospitalization compared with adults with asthma and normal testosterone levels, according to data presented at the AACE annual meeting.
Testosterone therapy not tied to additional metabolic benefits for older men with obesity
Testosterone therapy did not improve cardiometabolic measures for older men with obesity and hypogonadism receiving lifestyle intervention, according to findings published in The Journal of Clinical Endocrinology & Metabolism.
Top in endocrinology: Diabetes tied to redlining; weighing costs of immune therapies
Diabetes is more common in historically redlined neighborhoods, and residents of those neighborhoods have higher exposure to adverse social factors like discrimination, poverty, decreased food access and unemployment, researchers said.
Testosterone therapy does not improve most psychosocial measures for men with hypogonadism
Testosterone replacement therapy did not improve most quality of life and psychosocial measures for men with pathological hypogonadism who were at high risk for type 2 diabetes, according to study findings.
Testosterone therapy does not slow progression to diabetes, increase odds for remission
Testosterone replacement therapy alone did not lower risk for progression from prediabetes to diabetes or increase the likelihood of type 2 diabetes remission among men with hypogonadism, according to study data.
Short-term testosterone therapy improves quality of life, sexual function for men
Testosterone therapy improves sexual function and quality of life for men with a baseline serum testosterone of less than 12 nmol/L, though less improvement was observed for older men and those with obesity, data show.
Testosterone treatment boosts hemoglobin levels for older men with anemia
Testosterone therapy increases hemoglobin levels for older men with anemia and is linked to a lower likelihood for developing anemia for men without the condition, according to study data.
Testosterone replacement does not improve steatotic liver disease for older men
Twelve months of testosterone replacement therapy did not improve metabolic dysfunction-associated steatotic liver disease in a group of older men with hypogonadism, according to a secondary analysis of the T Trials.